US FTC suspends challenge to block Amgen’s $27.8 billion deal for Horizon Therapeutics

US FTC suspends challenge to block Amgen’s $27.8 billion deal for Horizon Therapeutics

The U.S. Federal Trade Commission (FTC) has temporarily halted its opposition to Amgen’s $27.8 billion acquisition of Horizon Therapeutics, according to a filing on Friday. The suspension will allow the FTC to consider settling the case. The pause will remain in effect until September 18.

Amgen has acknowledged the FTC’s decision and is ready to demonstrate in court that there are no legal or factual grounds to block the acquisition. The company expressed its preference for honoring its commitment rather than going through a lengthy court process. Amgen expects to complete the acquisition by mid-December this year.

In an unusual move to block a major pharmaceutical deal, the FTC filed a lawsuit on May 16 against the transaction. The agency’s opposition to the deal stems from concerns that Amgen may use its best-selling drugs to pressure insurance companies and pharmacy benefit managers into providing favorable terms for Horizon’s key products, Tepezza and Krystexxa.

Amgen announced its intention to acquire Horizon in December of last year, citing the potential protection from drug pricing provisions offered by Horizon’s rare disease drugs. These provisions are aimed at drugs commonly used by the government’s Medicare health plan. The agency and Amgen are scheduled to meet in Chicago federal court in September to discuss the injunction.

Horizon Therapeutics has not yet responded to a request for comment from RushHourDaily.

Reporting by Urvi Dugar in Bengaluru; editing by Jason Neely and Diane Craft.

About News Team

Hi, I'm Alex Perez, an experienced writer with a focus on lifestyle and culture news. From food and fashion to travel and entertainment, I love exploring the latest trends and sharing my insights with readers. I also have a strong interest in world news and business, and enjoy covering breaking stories and events.

Have a tip we should know?

Most Read

  1. ARTS
    With a Vengeance and no Apologies, Art Basel Miami Beach Has Returned
    2 years ago
  2. Food
    Is Faux Turkey Finally Vegan-Approved for Thanksgiving?
    2 years ago
  3. News
    Pandora Papers Financial Leak Shows Us the Secrets of the World’s Rich and Powerful
    2 years ago
  4. Health
    US Supreme Court Rejects J & J TALC Cancer Case Appeal
    2 years ago
  5. Lifestyle
    9 Habits that Drain your Daily Focus and How to Avoid Them
    2 years ago
    Women’s Demand for Shapewear – the big Trends
    2 years ago
    Valentino Launches its Cosmetics Line
    2 years ago
  8. Business
    McDonald’s Sales Increase Amid COVID Restrictions
    2 years ago
  9. Health
    US Promises to Share 60 million Doses of AstraZeneca Vaccines
    2 years ago
  10. coronavirus
    UK Offers Aid Amid Surging COVID-19 Cases in India
    2 years ago
  11. Entertainment
    Nomadland Director Chloé Zhao, Wins the Best Director in 2021 Oscar
    2 years ago
    Germany’s Birkenstock targets $9.2 billion valuation in New York IPO
    28 mins ago
  13. Drug & Device Trials
    Hungarian and US scientists win medicine Nobel for COVID-19 vaccine discoveries
    28 mins ago
  14. Sports
    North Korea sets another weightlifting world record at Asian Games
    29 mins ago
    Europe’s stocks eke out gains, yen lurks near 150
    1 hour ago
  16. Europe
    Kyiv brushes off US, Slovakia wobbles as EU ministers come to town
    1 hour ago
  17. Sports
    Permutations ahead of final pool matches at the Rugby World Cup
    1 hour ago
    In the Market: US bond market signals the end of an era
    2 hours ago

Follow @rushhourdaily: